Aurigene Pharmaceutical Services provides a flexible and wide range of services and capabilities at each phase of drug lifecycle.
- End-to-end services across the drug lifecycle.
- Integrated services and resources enabling seamless and accelerated development from discovery to commercialization.
- Capabilities to supply from gram scale to multi-ton scale of active ingredients and complex intermediates.
- Core areas of competence in specialized chemistry (peptides, carbohydrates, steroids, mPEGs).
- Standalone and integrated discovery services.
- World-class infrastructure: State-of-the-art R and D and manufacturing facilities audited by major international regulatory agencies.
- Biotherapeutic modalities including proteins, antibodies, ADCs, CAR Ts, mRNAs.
- Drug product capabilities from formulation development to commercial production in GMP facilities.
-
Hit Generation
-
Lead
Identification -
Lead
Optimization
- Early stage drug discovery accelerating innovations for small and large molecules.
- FTE/FFS services in medicinal chemistry, computational chemistry, discovery biology. and large molecule modalities.
-
Development
Phase 1 -
Development:
Phase 2 -
Development:
Phase 3
- Helping our partners to bring their innovations to the market faster through phase appropriate development services.
- Process development and non-GMP supplies and technology transfer.
- GMP clinical supplies for API and drug product.
Commercial
Manufacturing
- Ensuring a sustainable supply of APIs and finished formulations.
- Continuous improvement and reliable commercial supplies from 8 US FDA inspected facilities.
Range of our services
Aurigene Pharmaceutical Services offers end-to-end capabilities across drug discovery, development and manufacturing of APIs and formulations. We have discovery, development and manufacturing operations in multiple technology platforms including carbohydrates, steroids, PEG derivatives, oligonucleotides, steroids, high-potent APIs and peptides. In addition, we run discovery scale and CDMO scale operations in biotherapeutics services such as ADCs, mAbs, mRNAs and CAR Ts.
Aurigene Pharmaceutical Services CRO/CDMO
Small
Molecules
Large Molecules
Biotherapeutics
Formulation
Services
Why Aurigene Pharmaceutical Services?
Our focus on scientific expertise and integrated services along with our strong fundamentals on quality infrastructure, sustainability operations, and information security makes us a preferred partner.
Truly integrated services
We offer one-stop solutions for
- Integrated Discovery chemistry and Biology services
- Small molecule and Large molecule services
- Services from early discovery to commercialization
- Global regulatory and quality expertise
- Pre-formulation and formulation service
- Analytical and purification expertise
Quality
- Our R and D site is US FDA inspected cGMP sites have multiple accreditations across globe, All our labs are GLP approved, animal facilities are AAALAC accredited
Science
- Strong technology platforms Niche/Sensitive/Complex chemistry expertise
Infrastructure
- 2 R and D centers, 8 US FDA inspected cGMP sites, AAALAC accredited vivarium
Information Security
- 360-degree information security coverage with adequate back-up plan, business continuity plan and information security interventions
Business Continuity
- Structured assurance and governance measures
People
- We strive to hire the best talent and train them,
700+ scientists, >95% of scientists are post-graduates or above
ESG
- Commitment to highest standards of Environment, Social and Governance; Dow Jones, CDP, PSCI, approved
Connect with our scientific experts for your drug discovery, development, and manufacturing needs
We understand that clear communication is essential to successful collaborations, and that's why we have a dedicated team that is always ready to help you. Whether you have questions about our services, want to discuss a potential partnership, or simply want to learn more about our company, we're here to help.
Our team of experts is dedicated to providing personalised solutions tailored to your unique needs. So, please don't hesitate to reach out to us. We look forward to hearing from you and helping you achieve your business goals.
Resources
OCTOBER 01, 2024
PROTACs: Research for a life without cancer
PROTACs: Proteolysis-targeting chimeras (PROTACs) are a rapidly evolving field with promising applications in cancer, neurodegenerative diseases, and other conditions where the regulation of protein levels is crucial. PROTACs are a novel class of small molecules designed to target specific proteins for degradation by the ubiquitin-proteasome sys...
Read More
Advancement in personalized medicine and how the CRDMO industry is part of the solution
Personalized medicine is transforming the healthcare landscape by customizing treatment plans to individual patients’ unique genetic, clinical and environmental characteristics. These are effective and less invasive treatments for a wide range of conditions. Contract Research, Development and Manufacturing Organizations (CRDMOs) play an important role...
Read More
Cell Line Development
We enable development of stable and high yielding recombinant Mammalian and Microbial lines. ...
Read More
Case study: Tackling CYP 2C9 inhibition challenges
The Problem: Active compounds in a project were found to be highly potent inhibitors of CYP 2C9 The compounds selectively inhibited CYP 2C9 with IC50 values <100 nM There was no considerable inhibition of the other CYP isoforms Our Mitigation Approach: CYP 2C9 inhibition data was generated for a larger set of co...
Read More
Synthesis of Anti-covid Drug Nirmatrelvir Using Flow Chemistry
2022
Synthesis of the anti-covid therapeutic Nirmatrelvir by using flow chemistry to enhance efficiency of amide to nitrile conversion in a functionally and Stereochemically Embellished environment. ...
Read More-
Discovery of MAP855, an Efficacious and Selective MEK1/2 Inhibitor with an ATP-Competitive Mode of Action.
2005
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...
Read More -
Wang-OSO3H catalyzed green synthesis of bioactive isoindolo[2,1- a ]quinazoline-5,11–dione derivatives: An unexpected observation
2005
The sulphonic acid-functionalized Wang resin (Wang-OSO3H) was explored as a polymeric and recov- erable acidic catalyst for the synthesis of isoindolo[2,1- a ]quinazoline-5,11–dione derivatives under green conditions. Thus the Wang-OSO3H ...
Read More -
Polycyclic Aromatic Compounds: A Simple and Efficient [(n-Bu3Sn)2MO4]n Catalyzed Synthesis of Quinazolinones and Dihydroquinazolinones
2005
A novel unprecedented approach for the synthesis of various quinazolinones and dihydroquinazolinones has been using [(n-Bu3Sn)2MO4]n as a catalyst. The reaction has been screened ...
Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.
Leaving already?
Don't forget to join us at
CPHI Worldwide 2023.
October 24th-26th, 2023 | Barcelona, Spain
Get ready to accelerate your drug’s journey to the market